Published in Lab Business Week, January 14th, 2007
Thalomid Capsules, 200 mg had annual sales of approximately $59 million for the 12 months ended October 2006, based on IMS sales data.
Barr filed its ANDA containing a paragraph IV certification for a generic version of Thalomid Capsules, 200 mg with the FDA in September 2006, and received notification of the application's acceptance for filing in December...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.